The use of cells to cure disease is rapidly gaining momentum. Nevertheless, the development of cell-based therapies has been impacted by the complexity of the product, i.e. both biological and logistical/manufacturing challenges, and the cost.
Due to this complex nature of cell therapy products, partnering for their successful commercial development seems inevitable to overcome these developmental challenges.
In this symposium, we aim to drive the translation of cell therapy from the bench to the bedside by facilitating increased levels of interaction between the various partners of the developmental value chain.
Wilfried Dalemans, CTO, Tigenix
Christophe Lahorte, Federal Agency for Medicines and Health Products
Gert Van Assche, UZLeuven
Jan Schrooten, Antleron
Nathalie Cools, University of Antwerp, copromotor, Anicells
Bart Van Acker, Managing Director, QbD
Griet Nuytinck, CEO, Group Nuytinck
Toon Lambrechts, KULeuven
Jan Schrooten, Managing director, Antleron
Vanessa Vankerckhoven, CEO, Novosanis
Peter Allard, Managing director, RightAway
Henk Joos, Managing Director, flanders.bio
Incubator Darwin, Galileilaan 15, 2845 NIEL
Free of charge but registration is mandatory